Detalhe da pesquisa
1.
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
Br J Haematol
; 198(2): 333-337, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491747
2.
Assessment of the information theory approach to evaluating time-to-event surrogate and true endpoints in a meta-analytic setting.
Pharm Stat
; 20(2): 335-347, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145928
3.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood
; 131(9): 955-962, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29255066
4.
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer
; 19(1): 366, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30999949
5.
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
BMC Cancer
; 17(1): 332, 2017 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28511673
6.
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Ann Hematol
; 96(2): 253-259, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27900446
7.
An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.
Pharm Stat
; 16(5): 322-333, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28544622
8.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 17(8): 1081-1093, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27345636
9.
Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
Br J Haematol
; 185(3): 595-598, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203489
10.
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
Clin Lymphoma Myeloma Leuk
; 22(11): e1009-e1018, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045021
11.
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Blood Adv
; 6(3): 1025-1037, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34941996
12.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
J Clin Oncol
; 39(18): 1959-1970, 2021 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739857
13.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
J Hematol Oncol
; 11(1): 122, 2018 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249277
14.
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.
Eur J Dermatol
; 28(6): 775-783, 2018 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30698147